CCO Slideset

Session VI: Immunotherapies and Vaccine Strategies

Source: 6th International Symposium on Translational Research in Oncology

Session VI: Immunotherapies and Vaccine Strategies

Program Directors:

Dennis J. Slamon, MD, PhD
John Crown, MD, MPH

Faculty:

John Glaspy, MD

CME CREDIT INFORMATION

Release Date: 01/28/08

Expiration Date: 01/27/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the mechanism of action of CTLA4
Discuss how CTLA4-blocking monoclonal antibodies can lead to sustained regression of tumors in patients
Summarize vaccine combinations with anti-CTLA4 blockade
Cite the rationale for MAGE-A3 as an antitumor target

Topics covered include:

Session VI: Immunotherapies and Vaccine Strategies

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.